WEGOVY (semaglutide) by Novo Nordisk is glucagon-like peptide-1 (glp-1) agonists [moa]. First approved in 2021.
Drug data last refreshed Yesterday
Glucagon-like Peptide-1 (GLP-1) Agonists
GLP-1 Receptor Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Worked on WEGOVY at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo